| Literature DB >> 32587529 |
Mitchell C Lock1, Ross L Tellam1, Jack R T Darby1, Jia Yin Soo1, Doug A Brooks1,2, Mike Seed3, Joseph B Selvanayagam4, Janna L Morrison1.
Abstract
AIMS: Animal models have been used to show that there are critical molecular mechanisms that can be activated to induce myocardial repair at specific times in development. For example, specific miRNAs are critical for regulating the response to myocardial infarction (MI) and improving the response to injury. Manipulating these miRNAs in small animal models provides beneficial effects post-MI; however it is not known if these miRNAs are regulated similarly in large mammals. Studying a large animal where the timing of heart development in relation to birth is similar to humans may provide insights to better understand the capacity to repair a developing mammalian heart and its application to the adult heart.Entities:
Keywords: cardiac; fetus; miRNA; myocardial infarction; regeneration
Year: 2020 PMID: 32587529 PMCID: PMC7298149 DOI: 10.3389/fphys.2020.00614
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Expression of the miR-15 family in sheep 3 days post-MI. Mean normalized expression (MNE) of miR-15a (A), miR-15b (B), miR-16 (C), miR-195 (D), and miR-497 (E) in Sham, Remote, Border zone, and Infarct Tissue. Superscript letters (Fetal Sheep; a, b and Adolescent Sheep; x, y) represent significance between tissue regions (Remote, Border and Infarct) at each age (P < 0.05). *Represents significantly different data from the sham animals at each age (P < 0.05). Analyses between tissue regions (Infarct vs. Border vs. Remote) at each age were assessed using a nested Analysis of variance (ANOVA). A Bonferroni post hoc test was performed with multiple comparisons for each tissue region against the Sham tissue. n = 5 per treatment group per age.
FIGURE 2qRT-PCR validation of miR-15 family target mRNA expression in sheep 3 days post-MI. Mean normalized expression (MNE) of BIRC5 (A), SPAG5 (B), CHEK1 (C), and CDK1 (D) in Sham, Remote, Border zone, and Infarct Tissue. Superscript letters (Fetal Sheep; a, b and Adolescent Sheep; x, y) represent significance between tissue regions (Remote, Border and Infarct) at each age (P < 0.05). *Represents significantly different data from the sham animals at each age (P < 0.05). Analyses between tissue regions (Infarct vs. Border vs. Remote) at each age were assessed using a nested Analysis of Variance (ANOVA). A Bonferroni post hoc test was performed with multiple comparisons for each tissue region against the Sham tissue. n = 5 per treatment group per age.
FIGURE 3qRT-PCR validation of miR-133a and mRNA target expression in sheep 3 days post-MI. Mean normalized expression (MNE) of miR-133a (A), GJA1 (B), CTGF (C), PGAM1 (D), and SRF (E) in Sham, Remote, Border zone, and Infarct Tissue. Superscript letters (Fetal Sheep; a, b and Adolescent Sheep; x, y) represent significance between tissue regions (Remote, Border, and Infarct) at each age (P < 0.05). *Represents significantly different data from the sham animals at each age (P < 0.05). Analyses between tissue regions (Infarct vs. Border vs. Remote) at each age were assessed using a nested Analysis of variance (ANOVA). A Bonferroni post hoc test was performed with multiple comparisons for each tissue region against the Sham tissue. n = 5 per treatment group per age.
FIGURE 4Principal component analysis (PCA) of miRNA expression using all samples. The ellipses show the 95% confidence level for each group. Each group consisted of samples from three animals. The variance explained in each principal component (PC) is shown in brackets. The PC2 dimension separated the groups on the basis of age while separation of groups along PC1 highlighted the infarction response for both ages. The fetal Remote and Border samples were near superimposable. The adolescent Border sample showed considerable variance along PC1.
miRNA expression k-means clusters.
| 1 | Increased in infarct | miR-21, miR-21a-5p, miR-451, miR-7641 |
| 2 | Increased in infarct | let-7j, miR-1273e, miR-1285, miR-155, miR-199a-3p, miR-21, miR-222a-3p, miR-223-3p, miR-2478, miR-25, miR-25-3p, miR-29a, miR-376c-3p, miR-381, miR-381-5p, miR-3957-3p, miR-451, miR-451b, miR-5100, miR-6236, miR-6240, miR-7977 |
| 3 | Increased in infarct | miR-106a, miR-1224-5p, miR-1246, miR-125b, miR-125b-5p, miR-1260, miR-1260a, miR-1260b, miR-1285, miR-1357, miR-1386, miR-142-3p, |
| 4 | Increased in infarct | let-7i, miR-1246, miR-1254, miR-127, miR-1273e, miR-1285, miR-140, |
| 5 | Increased in infarct | miR-451, miR-7641, miR-21 |
| 6 | Decreased in infarct | let-7e-5p, miR-1, miR-100, miR-1285, |
| 7 | Decreased in infarct | miR-1, |
| 9 | Decreased in infarct | miR-133c, miR-145, miR-30a-5p, miR-30b, miR-30b-5p, miR-30c, miR-30c-5p, miR-30d, miR-30e-5p, miR-30f, miR-499 |
| 10 | Decreased in infarct | miR-125a, miR-125a-5p, miR-1386, miR-1538-p3, miR-181a-5p, miR-181c, miR-2487-p5, miR-30d, miR-4448, miR-4454, miR-5100, miR-6240-p3, miR-716a-p5, miR-716b |
| 1 | Increased in infarct | let-7j, miR-1260b, miR-1285, mir-1538, |
| 2 | Decreased in infarct | miR-34a, miR-125b, miR-125b-5p, |
| 3 | Increased in infarct | let-7i, miR-106a, miR-106b, miR-1224-5p, miR-1260b, miR-127, miR-1386, miR-150, miR-155, |
| 4 | Increased in infarct | miR-106a, miR-1246, miR-1260, miR-1260a, miR-1260b, miR-1285, miR-1357, miR-142-3p, |
| 5 | Decreased in infarct | miR-1, miR-100, miR-103-3p, miR-125a, miR-125a-5p, |
| 6 | Increased in infarct | miR-1246, miR-1254, miR-1273e, miR-1285, |
| 7 | Increased in infarct | miR-7641 |
| 8 | Decreased in infarct | miR-1, |
| 9 | Increased in infarct | miR-1273e, miR-21, miR-451, miR-7641 |
| 10 | Increased in infarct | miR-21, miR-21a-5p, miR-7641 |
Top 10 KEGG pathway enrichment terms for predicted targets of uniquely deregulated miRNAs in the infarct compared to remote samples.
| Predicted targets of fetal up-regulated miRNAs | Axon guidance | map04360 | 98 | 0.000 |
| Pathways in cancer | map05200 | 180 | 0.000 | |
| FoxO signaling pathway | map04068 | 73 | 0.0091 | |
| Proteoglycans in cancer | map05205 | 101 | 0.0091 | |
| MAPK signaling pathway | map04010 | 119 | 0.0091 | |
| Insulin signaling pathway | map04910 | 75 | 0.0091 | |
| ErbB signaling pathway | map04012 | 51 | 0.0102 | |
| Ras signaling pathway | map04014 | 109 | 0.0102 | |
| AMPK signaling pathway | map04152 | 68 | 0.0109 | |
| Regulation of actin cytoskeleton | map04810 | 103 | 0.0109 | |
| Predicted targets of fetal down-regulated miRNAs | Axon guidance | map04360 | 119 | 0.000 |
| Ras signaling pathway | map04014 | 142 | 0.000 | |
| Pathways in cancer | map05200 | 229 | 0.000 | |
| AMPK signaling pathway | map04152 | 87 | 0.007 | |
| Oxytocin signaling pathway | map04921 | 101 | 0.0081 | |
| ErbB signaling pathway | map04012 | 64 | 0.0081 | |
| Neurotrophin signaling pathway | map04722 | 82 | 0.0081 | |
| cAMP signaling pathway | map04024 | 119 | 0.0106 | |
| MAPK signaling pathway | map04010 | 145 | 0.0113 | |
| Sphingolipid signaling pathway | map04071 | 82 | 0.0113 | |
| Predicted targets of adolescent up-regulated miRNAs | Endocytosis | map04144 | 123 | 0.000 |
| Axon guidance | map04360 | 81 | 0.0055 | |
| Ras signaling pathway | map04014 | 98 | 0.0055 | |
| Regulation of actin cytoskeleton | map04810 | 95 | 0.0055 | |
| Neurotrophin signaling pathway | map04722 | 62 | 0.0055 | |
| AMPK signaling pathway | map04152 | 62 | 0.0069 | |
| Rap1 signaling pathway | map04015 | 91 | 0.0069 | |
| Fc gamma R | map04666 | 47 | 0.0069 | |
| Pathways in cancer | map05200 | 150 | 0.0082 | |
| cAMP signaling pathway | map04024 | 85 | 0.0082 | |
| Predicted targets of adolescent down-regulated miRNAs | MAPK signaling pathway | map04010 | 169 | 0.000 |
| Axon guidance | map04360 | 127 | 0.000 | |
| Wnt signaling pathway | map04310 | 106 | 0.000 | |
| Pathways in cancer | map05200 | 258 | 0.000 | |
| Proteoglycans in cancer | map05205 | 136 | 0.0041 | |
| FoxO signaling pathway | map04068 | 98 | 0.0041 | |
| Ras signaling pathway | map04014 | 152 | 0.0041 | |
| cAMP signaling pathway | map04024 | 130 | 0.0072 | |
| Oxytocin signaling pathway | map04921 | 107 | 0.0078 | |
| ErbB signaling pathway | map04012 | 67 | 0.0078 |
Top 10 gene ontology biological process terms for predicted mRNA targets of uniquely deregulated miRNAs.
| Predicted targets of fetal up-regulated miRNAs | Protein ubiquitination | GO:0016567 | 153 | 0.0001 |
| Response to ATP | GO:0033198 | 38 | 0.0003 | |
| Peptidyl-serine phosphorylation | GO:0018105 | 114 | 0.0007 | |
| Adenosine catabolic process | GO:0006154 | 23 | 0.0007 | |
| Intracellular signal transduction | GO:0035556 | 213 | 0.0007 | |
| Protein dephosphorylation | GO:0006470 | 98 | 0.0011 | |
| Cellular response to heat | GO:0034605 | 39 | 0.0013 | |
| Positive regulation of NF-kappaB transcription factor activity | GO:0051092 | 88 | 0.0014 | |
| Canonical Wnt signaling pathway | GO:0060070 | 111 | 0.0015 | |
| Wnt signaling pathway | GO:0016055 | 127 | 0.0017 | |
| Predicted targets of fetal down-regulated miRNAs | Water transport | GO:0006833 | 44 | 0.0008 |
| Positive regulation of MAPK cascade | GO:0043410 | 83 | 0.0011 | |
| Peptidyl-serine phosphorylation | GO:0018105 | 139 | 0.0014 | |
| Intracellular signal transduction | GO:0035556 | 262 | 0.0016 | |
| Endocytosis | GO:0006897 | 131 | 0.0035 | |
| Protein ubiquitination | GO:0016567 | 174 | 0.0037 | |
| Peptidyl-tyrosine dephosphorylation | GO:0035335 | 44 | 0.0039 | |
| Response to ATP | GO:0033198 | 40 | 0.0041 | |
| Protein polyubiquitination | GO:0000209 | 89 | 0.0045 | |
| Actin cytoskeleton organization | GO:0030036 | 104 | 0.0052 | |
| Predicted targets of adolescent up-regulated miRNAs | Nervous system development | GO:0007399 | 192 | 0.0001 |
| Intracellular signal transduction | GO:0035556 | 193 | 0.0002 | |
| Sensory perception of sound | GO:0007605 | 107 | 0.0006 | |
| Neuron migration | GO:0001764 | 90 | 0.0008 | |
| Collagen fibril organization | GO:0030199 | 44 | 0.001 | |
| Endocytosis | GO:0006897 | 97 | 0.0011 | |
| Intracellular protein transport | GO:0006886 | 107 | 0.0012 | |
| Positive regulation of I-kappaB kinase/NF-kappaB signaling | GO:0043123 | 83 | 0.0015 | |
| Memory | GO:0007613 | 54 | 0.0016 | |
| Peptidyl-serine phosphorylation | GO:0018105 | 98 | 0.0018 | |
| Predicted targets of adolescent down-regulated miRNAs | Neuron migration | GO:0001764 | 141 | 0.0001 |
| Peptidyl-serine phosphorylation | GO:0018105 | 153 | 0.0004 | |
| Intracellular signal transduction | GO:0035556 | 288 | 0.0004 | |
| Protein autophosphorylation | GO:0046777 | 175 | 0.0011 | |
| Protein localization to plasma membrane | GO:0072659 | 117 | 0.0012 | |
| Canonical Wnt signaling pathway | GO:0060070 | 147 | 0.0015 | |
| Nervous system development | GO:0007399 | 134 | 0.0015 | |
| cAMP catabolic process | GO:0006198 | 21 | 0.0015 | |
| Protein ubiquitination | GO:0016567 | 189 | 0.0019 | |
| Actin cytoskeleton organization | GO:0030036 | 59 | 0.0025 |
FIGURE 5Venn diagram of differentially expressed miRNAs in the Infarct samples compared to Remote samples and Border samples in fetal and adolescent sheep. n = 3 per age group. Only miRNAs that were significantly upregulated or downregulated are shown (P < 0.05).
FIGURE 6Aurora B immunohistochemistry staining. Representative micrographs of Aurora B immunohistochemistry staining (marker of cells entering cytokinesis) of H9c2 cardiomyoblasts after treatment with Hypoxia (1% O2). (A) Example of midbody staining in cells undergoing cytokinesis. (B) Negative control miRNA. (C) miR-558 inhibitor. Arrows indicate positive staining.
FIGURE 7Cell proliferation measures. (A) MTS cell proliferation assay. Background corrected proliferation assay absorbance of test anti-miRNAs. (B) % DAB Positive cells stained using an anti-Aurora-B antibody in 80 counting frames (Negative Control anti-miRNA, anti-miR-558, anti-miR-1538, anti-miR-150) on H9c2 cardiomyoblasts under Normoxia/Hypoxia or Glucose/Low Glucose conditions. *Represents significantly different data from the Negative Control miR group (P < 0.05). Nx, normoxia; LG, low glucose; Hx, hypoxia. Mean ± Standard Deviation.
FIGURE 8Target gene expression of anti-miRNAs. Mean normalized expression (MNE) of predicted target genes of anti-miRNAs, PAPPA (A), NF2 (B), JAG (C), MYOC1 (D), and SOX4 (E) demonstrating successful inhibition of miRNA resulting in decreased inhibition of target mRNAs. *Represents significantly different data from the negative control group (P < 0.05). n = 4 per treatment group.
FIGURE 9Linear regression of PAPPA and MYOC1 expression against measures of proliferation. Mean normalized expression of predicted target genes of anti-miRNAs against MTS and Aurora B proliferation measures demonstrating effectiveness of miRNA treatments within each oxygen environment.